Background: Thyroid hormones are essential to maintain the tissue's metabolism throughout the life. Thyroid hormones exert their effects on physiology and almost all body functions. Carrot is a rich source of iodine and carotenoids that can interfere in the synthesis of thyroid hormones.

Materials And Methods: The present study was designed to investigate the effects of carrot consumption on T4 levels and its effect on memory, nerve conduction velocity (NCV), animal weight, and finally, on water and food intake in Wistar rats. In this study, 24 male rats were used and divided into three groups: Control, Ca 200 mg/kg, and Ca 400 mg/kg.

Results: The results indicated that carrot consumption at Ca 200 mg/kg treated group increased the level of serum T4 and induced hyperthyroidism. Animal weight in both treated groups did not change compared to the control group ( > 0.05). Water and food consumption, and the level of T4 in Ca 200 mg/kg group increased when compared to the control group ( < 0.05). NCV in both treated groups was not significantly different in comparison with the control group ( > 0.05). Spatial memory and passive avoidance memory in both treated groups significantly decreased compared to the control group ( < 0.05).

Conclusion: Carrot consumption, via increases the synthesis of thyroid hormones, creates hyperthyroidism, but due to induced moderate hyperthyroidism did not impact on weight. Moderate hyperthyroidism induced appetite and memory impairment. Then increased food intake or effect of hyperthyroidism on metabolism increased water intake.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977616PMC
http://dx.doi.org/10.4103/abr.abr_178_20DOI Listing

Publication Analysis

Top Keywords

control group
16
thyroid hormones
12
carrot consumption
12
200 mg/kg
12
treated groups
12
compared control
12
group 005
12
memory nerve
8
nerve conduction
8
conduction velocity
8

Similar Publications

Background: Immunotherapy of Alzheimer's disease (AD) is a promising approach to reducing the accumulation of beta-amyloid, a critical event in the onset of the disease. Targeting the group II metabotropic glutamate receptors, mGluR2 and mGluR3, could be important in controlling Aβ production, although their respective contribution remains unclear due to the lack of selective tools.

Method: 5xFAD mice were chronically treated by a brain penetrant camelid single domain antibody (VHH or nanobody) that is an activator of mGluR2.

View Article and Find Full Text PDF

Background: Studies suggest a potential link between stroke and Alzheimer's disease wherein stroke may serve as a trigger for the onset or acceleration of Alzheimer's pathogenesis as damage to the brain's blood vessels may lead to the accumulation of amyloid beta protein which is a hallmark of Alzheimer's disease. Recent research has shown that stroke treatment may hold the key to treating Alzheimer's disease. The anti-inflammatory potentials of Cholinergic signaling are a novel therapeutic target in memory decline associated with Alzheimer's.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is a neurodegenerative disorder without a cure. Targeting this multifactorial disease by repurposing FDA approved drugs serves as a faster mode of treatment due to its pre-established human safety. We tested terazosin (TZ), an a-1 adrenergic receptor (AR) antagonist and phosphoglycerate kinase-1 (PGK1) activator as having potential to treat AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

STEM Neurology & Neuropsychological0 Research Group Egypt (SNRGE), Port Said, Port Said, Egypt.

Background: Donepezil, an acetylcholinesterase inhibitor (AChEI), is an FDA-approved drug to treat these neurodegenerative diseases, e.g., Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: Clinical trials should strive to yield results that are clinically meaningful rather than solely relying on statistical significance. However, the determination of clinical meaningfulness of dementia clinical trials lacks standardization and varies based on the trial's nature. To tackle this issue, a proposed approach involves assessing the time saved before reaching a specific threshold in cognitive status.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!